Search

Your search keyword '"Yang, Ju Dong"' showing total 977 results
Start Over Author "Yang, Ju Dong"
977 results on '"Yang, Ju Dong"'

156. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy

Author

Debes, Jose D., Chan, Aaron J., Balderramo, Domingo, Kikuchi, Luciana, Gonzalez Ballerga, Esteban, Prieto, Jhon E., Tapias, Monica, Idrovo, Victor, Davalos, Milagros B., Cairo, Fernando, Barreyro, Fernando J., Paredes, Sebastian, Hernandez, Nelia, Avendaño, Karla, Diaz Ferrer, Javier, Yang, Ju Dong, Carrera, Enrique, Garcia, Jairo A., Mattos, Angelo Z., Hirsch, Bruno S., Gonçalves, Pablo T., Carrilho, Flair J., and Roberts, Lewis R.

Published
2018
Full Text
View/download PDF

158. Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America

Author

Chan, Aaron J., Balderramo, Domingo, Kikuchi, Luciana, Ballerga, Esteban Gonzalez, Prieto, Jhon E., Tapias, Monica, Idrovo, Victor, Davalos, Milagros B., Cairo, Fernando, Barreyro, Fernando J., Paredes, Sebastian, Hernandez, Nelia, Avendaño, Karla, Ferrer, Javier Diaz, Yang, Ju Dong, Carrera, Enrique, Mattos, Angelo Z., Hirsch, Bruno S., Gonçalves, Pablo T., Carrilho, Flair J., Roberts, Lewis R., and Debes, Jose D.

Published
2017
Full Text
View/download PDF

161. Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018

Author

Truong, Emily, primary, Yeo, Yee Hui, additional, Cook‐Wiens, Galen, additional, Muthiah, Mark, additional, Yang, Ju Dong, additional, Sundaram, Vinay, additional, Chang, Devon, additional, Todo, Tsuyoshi, additional, Kim, Irene K., additional, Lu, Shelly C., additional, Setiawan, Veronica Wendy, additional, Wong, Vincent W. S., additional, Harrison, Stephen A., additional, Alkhouri, Naim, additional, and Noureddin, Mazen, additional

Published
2022
Full Text
View/download PDF

163. 950: REAL-WORLD EFFECTIVENESS AND RACIAL/ETHNIC DISPARITIES IN IMMUNOTHERAPY FOR ADVANCED HEPATOCELLULAR CARCINOMA: ANALYSIS OF US NATIONAL CANCER DATABASE

Author

Ahn, Joseph C., primary, Lauzon, Marie, additional, Luu, Michael, additional, Noureddin, Mazen, additional, Ayoub, Walid S., additional, Kuo, Alexander, additional, Sundaram, Vinay, additional, Kosari, Kambiz, additional, Nissen, Nicholas N., additional, Gong, Jun, additional, Hendifar, Andrew, additional, Roberts, Lewis R., additional, Abou-Alfa, Ghassan K., additional, Singal, Amit G., additional, and Yang, Ju Dong, additional

Published
2022
Full Text
View/download PDF

164. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States

Author

Ahn, Joseph C., primary, Lauzon, Marie, additional, Luu, Michael, additional, Noureddin, Mazen, additional, Ayoub, Walid, additional, Kuo, Alexander, additional, Sundaram, Vinay, additional, Kosari, Kambiz, additional, Nissen, Nicholas, additional, Gong, Jun, additional, Hendifar, Andrew, additional, Roberts, Lewis R., additional, Abou‐Alfa, Ghassan K., additional, Singal, Amit G., additional, and Yang, Ju Dong, additional

Published
2022
Full Text
View/download PDF

168. Reply

Author

Singal, Amit G., Daher, Darine, Seif El Dahan, Karim, Rich, Nicole E., Yang, Ju Dong, and Parikh, Neehar D.

Published
2024
Full Text
View/download PDF

175. HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis

Author

Singal, Amit G., Zhang, Emily, Narasimman, Manasa, Rich, Nicole E., Waljee, Akbar K., Hoshida, Yujin, Yang, Ju Dong, Reig, Maria, Cabibbo, Giuseppe, Nahon, Pierre, Parikh, Neehar D., and Marrero, Jorge A

Subjects
Article
Abstract

BACKGROUND: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given a lack of randomized controlled data. To address this issue, we conducted a systematic review and meta-analysis of cohort studies evaluating benefits and harms of HCC surveillance in patients with cirrhosis. METHODS: We performed a search of the Medline and EMBASE databases and national meeting abstracts from January 2014 through July 2020 for studies reporting early-stage HCC detection, curative treatment receipt, or overall survival, stratified by HCC surveillance status, among patients with cirrhosis. Pooled risk ratios and hazard ratios, according to HCC surveillance status, were calculated for each outcome using the DerSimonian and Laird method for random effects models. RESULTS: We identified 59 studies with 145,396 patients with HCC, of whom 41,052 (28.2%) were detected by surveillance. HCC surveillance was associated with improved early-stage detection (RR 1.86, 95%CI 1.73 – 1.98; I(2)=82%), curative treatment receipt (RR 1.83, 95%CI 1.69 – 1.97; I(2)=75%), and overall survival (HR 0.67, 95%CI 0.61 – 0.72; I(2)=78%) after adjusting for lead-time bias; however, there was notable heterogeneity in all pooled estimates. Four studies examined surveillance-related physical harms due to false positive or indeterminate surveillance results, but no studies examined potential financial or psychological harms. The proportion of patients experiencing surveillance-related physical harms ranged from 8.8% to 27.5% across studies, although most harms were mild in severity. CONCLUSION: HCC surveillance is associated with improved early detection, curative treatment receipt, and survival in patients with cirrhosis, although there was heterogeneity in pooled estimates. Available data suggest HCC surveillance is of high value in patients with cirrhosis, although continued rigorous studies evaluating benefits and harms are still needed.

Published
2022

188. Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting

Author

Lee, Yi‐Te, primary, Sun, Na, additional, Kim, Minhyung, additional, Wang, Jasmine J., additional, Tran, Benjamin V., additional, Zhang, Ryan Y., additional, Qi, Dongping, additional, Zhang, Ceng, additional, Chen, Pin‐Jung, additional, Sadeghi, Saeed, additional, Finn, Richard S., additional, Saab, Sammy, additional, Han, Steven‐Huy B., additional, Busuttil, Ronald W., additional, Pei, Renjun, additional, Zhu, Yazhen, additional, Tseng, Hsian‐Rong, additional, You, Sungyong, additional, Yang, Ju Dong, additional, and Agopian, Vatche G., additional

Published
2021
Full Text
View/download PDF

195. Abstract 764: Circulating tumor cell-based mRNA scoring system for prognostication of hepatocellular carcinoma - Translating HCC tissue-based mRNA profiling into a non-invasive setting

Author

Lee, Yi-Te, primary, Sun, Na, additional, Kim, Minhyung, additional, Wang, Jasmine J., additional, Tran, Benjamin V., additional, Zhang, Ryan Y., additional, Zhang, Ceng, additional, Sadeghi, Saeed, additional, Finn, Richard S., additional, Saab, Sammy, additional, Busuttil, Ronald W., additional, Zhu, Yazhen, additional, Tseng, Hsian-Rong, additional, You, Sungyong, additional, Yang, Ju Dong, additional, and Agopian, Vatche G., additional

Published
2021
Full Text
View/download PDF

196. Reply

Author

Yang, Ju Dong, Guy, Cynthia D., and Suzuki, Ayako

Published
2015
Full Text
View/download PDF

197. Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma.

Author

Teng, Pai‐Chi, Agopian, Vatche G, Lin, Ting‐Yi, You, Sungyong, Zhu, Yazhen, Tseng, Hsian‐Rong, and Yang, Ju Dong

Subjects
HEPATOCELLULAR carcinoma, INDIVIDUALIZED medicine, PROGNOSIS, TUMOR markers, POLYMERASE chain reaction
Abstract

Serum alpha‐fetoprotein and radiologic imaging are the most commonly used tests for early diagnosis and dynamic monitoring of treatment response in hepatocellular carcinoma (HCC). However, the accuracy of these tests is limited, and they may not reflect the underlying biology of the tumor. Thus, developing highly accurate novel HCC biomarkers reflecting tumor biology is a clinically unmet need. Circulating tumor cells (CTCs) have long been proposed as a noninvasive biomarker in clinical oncology. Most CTC assays utilize immunoaffinity‐based, size‐based, and/or enrichment‐free mechanisms followed by immunocytochemical staining to characterize CTCs. The prognostic value of HCC CTC enumeration has been extensively validated. Subsets of CTCs expressing mesenchymal markers are also reported to have clinical significance. In addition, researchers have been devoting their efforts to molecular characterizations of CTCs (e.g. genetics and transcriptomics) as molecular profiling can offer a more accurate readout and provide biological insights. As new molecular profiling techniques, such as digital polymerase chain reaction, are developed to detect minimal amounts of DNA/RNA, several research groups have established HCC CTC digital scoring systems to quantify clinically relevant gene panels. Given the versatility of CTCs to provide intact molecular and functional data that reflects the underlying tumor, CTCs have great potential as a noninvasive biomarker in HCC. Large‐scale, prospective studies for HCC CTCs with a standardized protocol are necessary for successful clinical translation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

200. Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma

Author

Moreno-Luna, Laura E., Yang, Ju Dong, Sanchez, William, Paz-Fumagalli, Ricardo, Harnois, Denise M., Mettler, Teresa A., Gansen, Denise N., de Groen, Piet C., Lazaridis, Konstantinos N., Narayanan Menon, K. V., LaRusso, Nicholas F., Alberts, Steven R., Gores, Gregory J., Fleming, Chad J., Slettedahl, Seth W., Harmsen, William S., Therneau, Terry M., Wiseman, Gregory A., Andrews, James C., and Roberts, Lewis R.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results